Xu Ma1, Qing-Yun Zhang. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Clinical Laboratory, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Abstract
OBJECTIVE: Plasminogen activator inhibitor-1 (PAI-1), one crucial component of the plasminogen activator system, is a major player in the pathogenesis of many vascular diseases as well as in cancer. High levels of PAI-1 in breast cancer tissue are associated with poor prognosis. The aim of this study is to evaluate rigorously the potential of serum PAI-1 concentration functioning as a general screening test in diagnostic or prognostic assays. METHODS: A protein-microarray-based sandwich fluorescence immunoassay (FIA) was developed to detect PAI-1 in serum. Several conditions of this microarray-based FIA were optimized to establish an efficacious method. Serum specimens of 84 healthy women and 285 women with breast cancer were analyzed using the optimized FIA microarray. RESULTS: The median serum PAI-1 level of breast cancer patients was higher than that of healthy women (109.7 ng/ml vs. 63.4 ng/ml). Analysis of covariance revealed that PAI-1 levels of the two groups were significantly different (P<0.001) when controlling for an age effect on PAI-1 levels. However, PAI-1 values in TNM stage I-IV patients respectively were not significantly different from each other. CONCLUSION: This microarray-based sandwich FIA holds potential for quantitative analysis of tumor markers such as PAI-1.
OBJECTIVE:Plasminogen activator inhibitor-1 (PAI-1), one crucial component of the plasminogen activator system, is a major player in the pathogenesis of many vascular diseases as well as in cancer. High levels of PAI-1 in breast cancer tissue are associated with poor prognosis. The aim of this study is to evaluate rigorously the potential of serum PAI-1 concentration functioning as a general screening test in diagnostic or prognostic assays. METHODS: A protein-microarray-based sandwich fluorescence immunoassay (FIA) was developed to detect PAI-1 in serum. Several conditions of this microarray-based FIA were optimized to establish an efficacious method. Serum specimens of 84 healthy women and 285 women with breast cancer were analyzed using the optimized FIA microarray. RESULTS: The median serum PAI-1 level of breast cancerpatients was higher than that of healthy women (109.7 ng/ml vs. 63.4 ng/ml). Analysis of covariance revealed that PAI-1 levels of the two groups were significantly different (P<0.001) when controlling for an age effect on PAI-1 levels. However, PAI-1 values in TNM stage I-IV patients respectively were not significantly different from each other. CONCLUSION: This microarray-based sandwich FIA holds potential for quantitative analysis of tumor markers such as PAI-1.
Entities:
Keywords:
Breast cancer; Plasminogen activator inhibitor-1; Protein microarray; Serum
Authors: Markus F Templin; Dieter Stoll; Monika Schrenk; Petra C Traub; Christian F Vöhringer; Thomas O Joos Journal: Trends Biotechnol Date: 2002-04 Impact factor: 19.536
Authors: Ulrike Weissenstein; Michael J Schneider; Michael Pawlak; Jonas Cicenas; Serenella Eppenberger-Castori; Peter Oroszlan; Sabine Ehret; Anneke Geurts-Moespot; Fred C G J Sweep; Urs Eppenberger Journal: Proteomics Date: 2006-03 Impact factor: 3.984
Authors: N Grebenchtchikov; T M Maguire; R Riisbro; A Geurts-Moespot; N O'Donovan; M Schmitt; G McGreal; E McDermott; N O'Higgins; N Brünner; C G J Sweep; M J Duffy Journal: Oncol Rep Date: 2005-07 Impact factor: 3.906
Authors: Eva Angenete; Marcus Langenskiöld; Ingrid Palmgren; Peter Falk; Tom Oresland; Marie-Louise Ivarsson Journal: J Surg Res Date: 2008-04-07 Impact factor: 2.192
Authors: Michelle K V Durand; Julie S Bødker; Anni Christensen; Daniel M Dupont; Martin Hansen; Jan K Jensen; Signe Kjelgaard; Lisa Mathiasen; Katrine E Pedersen; Sune Skeldal; Troels Wind; Peter A Andreasen Journal: Thromb Haemost Date: 2004-03 Impact factor: 5.249